0129 Servier
BioCentury & Flourish Studio

Product Development

Servier’s American cancer experiment

How Servier has built out its cancer capabilities and U.S. presence

A string of deals, including two over $1 billion, have given Servier a cancer focus with programs across four modalities and a growing presence in the U.S.

Jan 29, 2021 | 10:21 PM GMT

Six years after Servier made its decision to pivot to cancer, the French pharma is on the cusp of being a major player in the space. Through a flurry of deals, the company has added capabilities across at least three modalities and an internal discovery and translational research engine with a fast-growing presence in the U.S.

The private company has its roots in the cardiovascular and diabetes space where it

Read the full 1202 word article

How to gain access

Continue reading with a
two-week free trial.